Fluid delivery system and controller for electrosurgical devices

Information

  • Patent Grant
  • 7815634
  • Patent Number
    7,815,634
  • Date Filed
    Monday, December 22, 2003
    21 years ago
  • Date Issued
    Tuesday, October 19, 2010
    14 years ago
Abstract
The invention provides a system for treating tissue that includes a power measurement device, a flow rate controller coupled to the power measurement device, and an electrosurgical device configured and arranged to provide radio frequency power and conductive fluid to the tissue, wherein the flow rate controller is configured and arranged to modify a flow rate of the conductive fluid to the tissue, based on signals from the power measurement device. The invention also provides methods and devices for modifying flow rate of conductive fluid to tissue based on measurement of radio frequency power delivered to the tissue.
Description
FIELD OF THE INVENTION

This invention relates to the field of devices for use in operative surgery upon tissues of the body. More particularly, the invention relates to electrosurgical methods and systems for treatment of body tissues.


BACKGROUND OF THE INVENTION

Electrosurgical devices use electrical energy, most commonly radio frequency (RF) energy, to cut tissue or to cauterize blood vessels. During use, a voltage gradient is created at the tip of the device, thereby inducing current flow and related heat generation in the tissue. With sufficiently high levels of electrical energy, the heat generated is sufficient to cut the tissue and, advantageously, to stop the bleeding from severed blood vessels.


Current electrosurgical devices can cause the temperature of tissue being treated to rise significantly higher than 100° C., resulting in tissue desiccation, tissue sticking to the electrodes, tissue perforation, char formation and smoke generation. Peak tissue temperatures as a result of RF treatment of target tissue can be as high as 320° C., and such high temperatures can be transmitted to adjacent tissue via thermal diffusion. Undesirable results of such transmission to adjacent tissue include unintended thermal damage to the tissue.


Using saline to couple RF electrical energy to tissue prevents such undesirable effects as sticking, desiccation, smoke production and char formation. One key factor is preventing tissue desiccation, which occurs if tissue temperature exceeds 100° C. and all of the intracellular water boils away, leaving the tissue extremely dry and much less electrically conductive. However, an uncontrolled flow rate of saline can provide too much cooling at the electrode/tissue interface. This cooling reduces the temperature of the target tissue being treated, and the rate at which tissue thermal coagulation occurs is determined by tissue temperature. This, in turn, can result in longer treatment time, to achieve the desired tissue temperature for cauterization or cutting of the tissue. Long treatment times are undesirable for surgeons since it is in the best interest of the patient, physician and hospital to perform surgical procedures as quickly as possible.


RF energy delivered to tissue is unpredictable and often not optimal when using general-purpose generators. Most general-purpose RF generators have modes for different waveforms (cut, coagulation, or a blend of these two) and device types (monopolar, bipolar), as well as power levels that can be set in watts. However, once these settings are chosen, the actual power delivered to tissue can vary dramatically over time as tissue impedance changes over the course of RF treatment. This is because the power delivered by most generators is a function of tissue impedance, with the power ramping down as impedance either decreases toward zero or increases significantly to several thousand ohms.


A further limitation of current electrosurgical devices arises from size constraints of the device in comparison to tissue that is encountered during a single surgical procedure. During the course of a single procedure, for example, a surgeon often encounters a wide variety of tissue sizes. Surgical devices often come in a variety of sizes because larger segments of tissue physically require commensurately larger electrode jaws or tips, but smaller segments of tissue often are not optimally treated by the much larger size RF device. It is undesirable to require numerous surgical devices during a single procedure, because this wastes valuable operating room time, can make it difficult to precisely relocate the treatment site, increases the risk of infection, and increases the cost by increasing the number of different surgical devices that are needed to complete the surgical procedure.


For example, a bipolar saline-enhanced tissue sealing forceps that has jaws long enough to effectively seal a 30 mm length of tissue may not be desirable for sealing a segment of tissue that is 10 mm in length. Excess saline from one of the electrode jaws (for a bipolar device) can flow to the other electrode in the space where there is no intervening tissue. This flow of electrically conductive saline can act as an electrical resistor in parallel with the electrical pathway through the target tissue. Electrical current flow through the saline can divert or shunt RF energy away from going through the target tissue, and slow down the rate at which the target tissue is heated and treated.


A surgeon may first be sealing and cutting lung tissue as part of a wedge resection using the full 30 mm jaw length 2-3 times to remove a tip of a lobe of lung for biopsy. If the intraoperative histopathology indicates that the suspected tissue has a malignant tumor, then the surgeon may convert the procedure to a lobectomy. As part of the lobectomy the surgeon will want to seal and cut large blood vessels that supply the lobe. Alternatively, the surgeon may want to toughen up or coagulate large vessels with RF and then apply a ligating clip to assure hemostasis before cutting. Even compressed, these blood vessels might only fill a small fraction of the 30 mm length of electrode jaw. For at least the reasons identified above, this is an undesirable situation with current electrosurgical devices.


SUMMARY OF THE INVENTION

The invention provides a system for treating tissue comprising a power measurement device, a flow rate controller coupled to the power measurement device, and an electrosurgical device configured and arranged to provide radio frequency power and conductive fluid to the tissue, wherein the flow rate controller is configured and arranged to modify a flow rate of the conductive fluid to the tissue, based on signals from the power measurement device.


Preferably, the flow rate controller modifies the flow rate of the conductive fluid to the tissue based on heat used to warm the conductive fluid and heat used to convert the conductive fluid to vapor. In a preferred embodiment, the flow rate controller modifies the flow rate of the conductive fluid to the tissue using the relationship:






K
=

1

{


ρ






c
p


Δ





T

+

ρ






h
v




Q
b

/

Q
l




}






In another embodiment, the invention provides a device for modifying flow rate of conductive fluid to tissue based on measurement of radio frequency power delivered to the tissue, the device comprising a flow rate controller configured and arranged to modify flow rate of the conductive fluid to the tissue, based on heat used to warm the conductive fluid and heat used to convert the conductive fluid to vapor. Preferably, the device modifies the flow rate of the conductive fluid to the tissue using the relationship:






K
=

1

{


ρ






c
p


Δ





T

+

ρ






h
v




Q
b

/

Q
l




}






In an alternative embodiment, the invention provides a device for treating tissue using radio frequency power and conductive fluid, the device comprising a sensing device, and a processor coupled to the sensing device, wherein the processor is configured and arranged to adjust flow rate of the conductive fluid to the tissue, by determining a level of radio frequency power applied to the tissue using the sensing device, and adjusting the flow rate of the conductive fluid to the tissue. Preferably, the processor is configured and arranged to adjust the flow rate of the conductive fluid to the tissue based on heat used to warm the conductive fluid and heat used to convert the conductive fluid to vapor. Preferably, the flow rate controller modifies the flow rate of the conductive fluid to the tissue using the relationship:






K
=

1

{


ρ






c
p


Δ





T

+

ρ






h
v




Q
b

/

Q
l




}






In another embodiment, the invention provides a method for treating tissue comprising applying radio frequency power and conductive fluid to the tissue using a surgical device, wherein the conductive fluid is provided to the tissue at a fluid flow rate, determining an amount of radio frequency power applied to the tissue, and modifying the fluid flow rate based on the power applied to the tissue. Preferably, the step of modifying the fluid flow rate based on the power applied to the tissue comprises modifying the flow rate of the conductive fluid to the tissue based on heat used to warm the conductive fluid and heat used to convert the conductive fluid to vapor. Preferably, the step of modifying the fluid flow rate based on the power applied to the tissue comprises determining the fluid flow rate using the relationship:






K
=

1

{


ρ






c
p


Δ





T

+

ρ






h
v




Q
b

/

Q
l




}






In an alternative embodiment, the invention provides a method for treating tissue comprising providing a surgical device comprising an electrode, wherein the surgical device is configured and arranged to receive radio frequency power and conductive fluid and deliver the radio frequency power and conductive fluid to the tissue, determining the radio frequency power applied to the tissue, and providing the conductive fluid to the tissue at a fluid flow rate, wherein the fluid flow rate is modified to control boiling of the conductive fluid at the tissue. Preferably, the step of providing the conductive fluid to the tissue at a fluid flow rate comprises providing the conductive fluid to the tissue based on heat used to warm the conductive fluid and heat used to convert the conductive fluid to vapor. In a preferred embodiment, the step of providing the conductive fluid to the tissue at a fluid flow rate comprises providing the conductive fluid to the tissue using the relationship:






K
=

1

{


ρ






c
p


Δ





T

+

ρ






h
v




Q
b

/

Q
l




}






In another embodiment, the invention provides a system for treating tissue comprising a power measurement device, a flow rate controller coupled to the power measurement device, a flow control device coupled to the flow rate controller, and an electrosurgical device coupled to the flow control device and the power measurement device, wherein the electrosurgical device is configured and arranged to provide radio frequency power and conductive fluid to the tissue, and wherein the flow rate controller is configured and arranged to modify a flow rate of the conductive fluid to the electrosurgical device, based on signals from the power measurement device. Preferably, the flow control device comprises a pump. In one embodiment, the pump comprises a peristaltic pump. In another embodiment, the pump comprises a syringe pump. Preferably, the electrosurgical device comprises a bipolar electrosurgical device.


According to this embodiment, the flow rate controller is preferably configured and arranged to modify the flow rate of the conductive fluid to the flow control device based on heat used to warm the conductive fluid and heat used to convert the conductive fluid to vapor. In a preferred embodiment, the flow rate controller is configured and arranged to modify the flow rate of the conductive fluid to the tissue using the relationship:






K
=

1

{


ρ






c
p


Δ





T

+

ρ






h
v




Q
b

/

Q
l




}






The invention can improve the speed of tissue coagulation provided by fluid-enhanced electrosurgery by assuring that the electrode-tissue interface is within a desired temperature range (for example, not significantly hotter than 100° C.) through the control of the fraction of conductive fluid that is boiled off at the electrode-tissue interface. This improvement can be achieved by measuring power provided to the device and regulating the flow of fluid to the device. Preferably, tissue sensors (for example, that would measure tissue temperature or tissue impedance) are not required according to the invention.


Some embodiments of the invention can provide one or more advantages, such as the ability to achieve the desired tissue effect (for example, coagulation, cutting, or the like) in a fast, effective manner. The invention can also provide the ability to treat tissue quickly without using a tissue sensor (for example, a temperature sensor) built into the device or a custom special-purpose generator. The invention can allow a surgeon to use a variety of electrosurgical devices with a wide variety of general-purpose generators. Further, the invention can provide the ability to use an electrosurgical device that is capable of quickly and effectively sealing a wide variety of tissue sizes and thicknesses.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a block diagram showing one embodiment of the overall control system of the invention, and an electrosurgical device.



FIG. 2 is a schematic graph that describes the relationship between RF power to tissue (P), flow rate of saline (Q), and tissue temperature (T).



FIG. 3 is schematic graph that describes the relationship between RF power to tissue (P), flow rate of saline (Q), and tissue temperature (T) when heat conduction to adjacent tissue is neglected.



FIG. 4 is a graph showing the relationship of percentage saline boiling and saline flow rate (cc/min) for an exemplary RF generator output of 75 watts.



FIG. 5 is a schematic graph that describes the relationship of load impedance (Z, in ohms) and generator output power (P, in watts), for an exemplary generator output of 75 watts in a bipolar mode.



FIG. 6 is a schematic graph that describes the relationship of time (t, in seconds) and tissue impedance (Z, in ohms) after RF activation.



FIG. 7 is a schematic side view of one embodiment of a bipolar electrosurgical device.



FIG. 8 is a schematic close-up section side view of the tip of the device shown in FIG. 7.



FIG. 9 is a schematic top view of the bipolar electrosurgical device shown in FIG. 7.



FIG. 10 is a schematic close-up section top view of the tip of the device shown in FIG. 9.



FIG. 11 is a schematic close-up section side view of the electrodes of the device shown in FIG. 9 showing saline shunting without boiling of the saline.



FIG. 11
a is a diagram that describes the equivalent electrical circuit for tissue in parallel with a single saline shunt.



FIG. 11
b is a graph that describes the relationship of ratio of saline to tissue resistance (Rs/Rt) and percent power shunted into saline.



FIG. 12 is a schematic close-up side section view of the electrodes of the device shown in FIG. 9 showing a large percentage of the saline boiling at the tissue treatment site.



FIG. 13 is a schematic close-up side section view of electrodes of the device shown in FIG. 9 showing two gutters slid out to direct saline flow distally toward tissue.



FIG. 14 is a schematic close-up cross-section view along line A-A of FIG. 9, showing the two gutters positioned to collect and direct saline flow distally.



FIG. 15 is a schematic close-up cross-section view of one embodiment of the jaws of the device shown in FIG. 9, wherein the jaws include a tissue-activated valve.



FIG. 16 is a schematic close-up side section view of one embodiment of the jaws of the device shown in FIG. 9, wherein the jaws include tissue-activated valves to direct flow distally.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Overview


The invention provides a system, device and methods that preferably improve control of tissue temperature at a treatment site during a medical procedure. The invention is particularly useful during surgical procedures upon tissues of the body, where tissue is often cut and coagulated. The invention involves the use of electrosurgical procedures, which utilize RF power and conductive fluid to treat tissue. Preferably, a desired tissue temperature range is achieved through, adjusting parameters, such as conductive fluid flow rate, that affect the temperature at the tissue/electrode interface. Preferably, the device achieves a desired tissue temperature utilizing a desired percentage boiling of the conductive solution at the tissue/electrode interface. In a preferred embodiment, the invention provides a control device, the device comprising a flow rate controller that receives a signal indicating power applied to the system, and adjusts the flow rate of conductive fluid from a fluid source to an electrosurgical device. The invention also contemplates a control system comprising a flow rate controller, a measurement device that measures power applied to the system, and a pump that provides fluid at a desired flow rate.


The invention will be discussed generally with reference to FIG. 1. FIG. 1 shows a block diagram of one embodiment of a system of the invention. As shown in FIG. 1, conductive fluid is provided from a fluid source 1, through a fluid line 2, to a pump 3, which has an outlet fluid line 4 that is connected to an electrosurgical device 5. In a preferred embodiment, the conductive fluid comprises saline, such as sterile, normal saline. Although the description herein will describe saline as a conductive fluid, one of skill in the art would understand, upon reading this disclosure, that other conductive fluids can be used in accordance with the invention. The conductive fluid can comprise physiologic saline (“normal” saline, or 0.9% NaCl solution), lactated Ringer's™, or the like.


A generator 6 provides RF energy via a cable 7 to a power measurement device 8 that measures the RF electrical power. In this embodiment, the power measurement device 8 does not turn the power off or on or alter the power in any way. A power switch 15 connected to the generator 6 is provided by the generator manufacturer and is used to turn the generator 6 on and off. The power switch 15 can comprise any switch to turn the power on and off, and is commonly provided in the form of a footswitch or other easily operated switch. A cable 9 carries RF energy from the power measurement device 8 to the electrosurgical device 5. Power is preferably measured before it reaches the electrosurgical device.


A flow rate controller 11 includes a selection switch 12 that can be set to achieve desired levels of percentage fluid boiling (for example, 100%, 98%, 80% boiling). The flow rate controller 11 receives a signal 10 from the power measurement device 8 and calculates the correct fluid flow rate based on percentage boiling indicated by the selection switch 12. In a preferred embodiment, a fluid switch 13 is provided so that the fluid system can be primed (air eliminated) before turning the generator 6 on. The output signal 16 of the flow rate controller 11 is sent to the pump 3 motor to regulate the flow rate of conductive fluid, and thereby provide an appropriate fluid flow rate for the amount of power being delivered.


Throughout the present description, like reference numerals and letters indicate corresponding structure throughout the several views, and such corresponding structure need not be separately discussed.


In one embodiment, the invention comprises a flow rate controller that is configured and arranged to be connected to a source of RF power, and a source of conductive fluid. The device of the invention receives information about the level of RF power applied to an electrosurgical device, and adjusts the flow rate of the conductive fluid to the electrosurgical device, thereby controlling temperature at the tissue treatment site.


In another embodiment, elements of the system are physically included together in one electronic enclosure. One such embodiment is shown by enclosure within the outline box 14 of FIG. 1. In the illustrated embodiment, the pump 3, flow rate controller 11, and power measurement device 8 are enclosed within an enclosure, and these elements are connected through electrical connections to allow signal 10 to pass from the power measurement device 8 to the flow rate controller 11, and signal 16 to pass from the flow rate controller 11 to the pump 3. Other elements of a system can also be included within one enclosure, depending upon such factors as the desired application of the system, and the requirements of the user.


The pump 3 can be any suitable pump used in surgical procedures to provide saline or other fluid at a desired flow rate. Preferably, the pump 3 comprises a peristaltic pump. Alternatively, pump 3 can be a “syringe pump,” with a built-in fluid supply; or a double-acting syringe pump with two syringes such that they can draw saline from a reservoir. Conductive fluid can also be provided from an intravenous (“I.V.”) bag full of saline that flows under the influence of gravity to the pump 3. Similar pumps can be used in connection with the invention, and the illustrated embodiments are exemplary only. The precise configuration of the pump 3 is not critical to the invention. In some embodiments, the pump can be substituted with any type of flow controller, to allow the user to control the flow rate of conductive fluid to the device. Alternatively, a valve configuration can be substituted for pump 3.


The components of the system will now be described in detail.


The Flow Rate Controller


The flow rate controller 11 controls the rate of flow from the fluid source 1, based upon the amount of RF power provided from the generator 6 to the electrosurgical device 5. The flow rate of conductive fluid, such as saline, interacts with the RF power and various modes of heat transfer away from the target tissue, as described herein.



FIG. 2 shows a schematic graph that describes the relationship between the flow rate of saline, RF power to tissue, and regimes of boiling. Based on a simple one-dimensional lumped parameter model of the heat transfer, the peak tissue temperature can be estimated, and once tissue temperature is estimated, it follows directly whether it is hot enough to boil saline.

P=ΔT/R+ρcρQlΔT+ρQbhv  (1)

Where P=the total RF electrical power that is converted into heat.


Conduction. The first term [ΔT/R] in equation (1) is heat conducted to adjacent tissue, represented as 70 in FIG. 2, where:

    • ΔT=(T−T) the difference in temperature between the peak tissue temperature (T) and the normal temperature (T) of the body tissue (° C.). Normal temperature of the body tissue is generally 37° C.; and
    • R=Thermal Resistance of surrounding tissue, the ratio of the temperature difference to the heat flow (° C./watt).


This thermal resistance can be estimated from published data gathered in experiments on human tissue (Phipps, J. H., “Thermometry studies with bipolar diathermy during hysterectomy,” Gynaecological Endoscopy, 3:5-7 (1994)). As described by Phipps, Kleppinger bipolar forceps were used with an RF power of 50 watts, and the peak tissue temperature reached 320° C. For example, using the energy balance of equation (1), and assuming all the RF heat put into tissue is conducted away, then R can be estimated:

R=ΔT/P=(320−37)/50=5.7≈6° C./watt


However, it is undesirable to allow the tissue temperature to reach 320° C., since tissue will become desiccated. At a temperature of 320° C., the fluid contained in the tissue is typically boiled away, resulting in the undesirable tissue effects described herein. Rather, it is preferred to keep the peak tissue temperature at no more than 100° C. to prevent desiccation of the tissue. Assuming that saline boils at 100° C., the first term in equation (1) (ΔT/R) is equal to (100−37)/6=10.5 watts. Thus, based on this example, the maximum amount of heat conducted to adjacent tissue without any significant risk of tissue desiccation is 10.5 watts.


Referring to FIG. 2, RF power to tissue is represented on the X-axis as P (watts) and flow rate of saline (cc/min) is represented on the Y-axis as Q. When the flow rate of saline equals zero (Q=0), there is an “offset” RF power that shifts the origin of the sloped lines 76, 78, and 80 to the right. This offset is the heat conducted to adjacent tissue. For example, using the calculation above for bipolar forceps, this offset RF power is about 10.5 watts. If the power is increased above this level with no saline flow, the peak tissue temperature can rise well above 100° C., resulting in tissue desiccation from the boiling off of water in the cells of the tissue.


Convection. The second term [ρcρQlΔT] in equation (1) is heat used to warm up the flow of saline without boiling the saline, represented as 72 in FIG. 2, where:

    • ρ=Density of the saline fluid that gets hot but does not boil (approximately 1.0 gm/cm3);
    • cρ=Specific heat of the saline (approximately 4.1 watt-sec/gm-° C.);
    • Ql=Flow rate of the saline that is heated (cm3/sec); and
    • ΔT=Temperature rise of the saline. Assuming that the saline is heated to body temperature before it gets to the electrode, and that the peak saline temperature is similar to the peak tissue temperature, this is the same ΔT as for the conduction calculation above.


The onset of boiling can be predicted using equation (1) with the last term on the right set to zero (no boiling) (ρQbhv=0), and solving equation (1) for Ql leads to:

Ql=[P−ΔT/R]/ρcρΔT  (2)

This equation defines the line shown in FIG. 2 as the line of onset of boiling 76. It is possible in some embodiments that the flow of conductive fluid can be nonuniformly heated, thereby reducing the term in the denominator of Equation (2), ρcρΔT. If the amount of convection is less due to nonuniformity of heating, conductive fluid boiling would occur sooner. In other words, the slope of the curve will be steeper at a given power, and conductive fluid will boil at a lower flow rate. This type of nonuniformity can be associated with device configurations and hence could be used to provide a level of control of convection. For example, for a particular type of device known to provide nonuniform heating of the conductive solution, the invention can provide an “offset” to take this into account to provide the desired level of boiling at the electrode/tissue interface.


Boiling. The third term [ρQbhv] in equation (1) relates to heat that goes into converting liquid saline to vapor saline and is represented as 74 in FIG. 2, where:

    • Qb=Flow rate of saline that boils (cm3/sec); and
    • hv=Heat of vaporization of saline (approximately 2,000 watt-sec/gm).


A flow rate of only 1 cc/min will absorb a significant amount of heat if it is completely boiled, or about ρQbhv=(1) ( 1/60) (2,000)=33.3 watts. The heat needed to warm this flow rate from body temperature to 100° C. is much less, or ρcρQlΔT=(1) (4.1) ( 1/60) (100−37)=4.3 watts. In other words, the most significant factor contributing to heat transfer from a wet electrode device can be fractional boiling. The present invention recognizes this fact and exploits it.


Fractional boiling can be described by equation (3) below:










Q
l

=


{

P
-

Δ






T
/
R







}


{


ρ






c
p


Δ





T

+

ρ






h
v




Q
b

/

Q
l




}






(
3
)







If the ratio of Qb/Ql is 0.50 this is the 50% boiling line 78 shown in FIG. 2. If the ratio is 1.0 this is the 100% boiling line 80 shown in FIG. 2.


Control Strategy


Since the amount of heat conducted away to adjacent tissue is difficult to precisely predict, it is preferable, from a control point of view, to assume the worst case situation of zero heat conduction, and provide enough saline so that if necessary, all the RF power could be used to heat up and boil the saline, thus providing that the peak tissue temperature will not go over 100° C. a significant amount. This situation is shown in the schematic graph of FIG. 3.


It is desirable to control the saline flow rate so that it is always on a “line of constant % boiling” for consistent tissue effect. If the device is monopolar and shunting through saline is not an issue, then it can be preferable to operate close to, but not over the line of the onset of boiling, 76a in FIG. 3. This preferably keeps tissue as hot as possible with causing desiccation. Alternatively, if the device is bipolar and shunting of electrical energy through excess saline is an issue, then it can be preferable to operate along a line of constant boiling such as line 78a in FIG. 3, the 50% line. This simple proportional control will have the flow rate determined by equation (4), where K is the proportionality constant:

Ql=K×P  (4)


In essence, when power P goes up, the flow rate Q will be proportionately increased. Conversely, when power P goes down, the flow rate Q will be proportionately decreased.


K is primarily dependent on the fraction of saline that boils, as shown in equation (5), which is equation (3) solved for K after eliminating P using equation (4), and neglecting the conduction term (ΔT/R):









K
=

1

{


ρ






c
p


Δ





T

+

ρ






h
v




Q
b

/

Q
l




}






(
5
)







Thus, the present invention provides a method of controlling boiling of conductive fluid at the tissue/electrode interface. In a preferred embodiment, this provides a method of treating tissue without use of tissue sensors, such as temperature or impedance sensors. Preferably, the invention can control boiling of conductive fluid at the tissue/electrode interface and thereby control tissue temperature without the use of feedback loops.



FIG. 4 shows an exemplary graph of flow rate versus % boiling for a situation where the RF power is 75 watts. The percent boiling is represented on the X-axis, and the saline flow rate (cc/min) is represented on the Y-axis. According to this example, at 100% boiling the most desirable saline flow rate is 2 cc/min.


As discussed herein, RF energy delivery to tissue can be unpredictable and vary with time, even though the generator has been “set” to a fixed wattage.


The schematic graph of FIG. 5 shows the general trends of the output curve of a typical general-purpose generator, with the output power changing as load (tissue plus cables) impedance changes. Load impedance (in ohms) is represented on the X-axis, and generator output power (in watts) is represented on the Y-axis. In the illustrated embodiment, the electrosurgical power (RF) is set to 75 watts in a bipolar mode. As shown in the figure, the power will remain constant as it was set as long as the impedance stays between two cut-offs of impedance, that is, between 50 ohms and 300 ohms in the illustrated embodiment. Below load impedance of 50 ohms, the power will decrease, as shown by the low impedance ramp 48. Above load impedance of 300 ohms, the power will decrease, as shown by the high impedance ramp 46. Of particular interest to saline-enhanced electrosurgery is the low impedance cut-off (low impedance ramp 48), where power starts to ramp down as impedance drops further.



FIG. 6 shows the general trend of how tissue impedance generally changes with time for saline-enhanced electrosurgery. As tissue heats up, the temperature coefficient of the tissue and saline in the cells is such that the tissue impedance decreases. Thus, as tissue heats up, the load impedance decreases, approaching the impedance cut-off of 50 ohms. Once tissue is sufficiently heated, such that the impedance cut-off is passed, the power decreases along the lines of the low impedance ramp 48 of FIG. 5.


Combining the effects shown in FIG. 5 and FIG. 6, it becomes clear that when using a general-purpose generator set to a “fixed” power, the actual power delivered can change dramatically over time as tissue heats up and impedance drops. Looking at FIG. 5, if the impedance drops from 100 to 75 ohms over time, the power output would not change because the curve is “flat” in that region of impedances. If, however, the impedance drops from 75 to 30 ohms one would “turn the corner” onto the low impedance ramp 48 portion of the curve and the power output would decrease dramatically.


According to the invention, the control device receives a signal indicating the drop in actual power delivered to the tissue and adjusts the flow rate of saline to maintain the tissue/electrode interface at a desired temperature. In a preferred embodiment, the drop in actual power delivered is sensed by the power measurement device 8 (shown in FIG. 1), and the flow rate of saline is decreased by the flow rate controller 11 (also shown in FIG. 1). Preferably, this reduction in saline flow rate allows the tissue temperature to stay as hot as possible without desiccation. If the control device was not in operation and the flow rate allowed to remain higher, the tissue would be over-cooled at the lower power input. This would result in decreasing the temperature of the tissue at the treatment site.


The flow rate controller 11 of FIG. 1 can be a simple “hard-wired” analog or digital device that requires no programming by the user or the manufacturer. The flow rate controller 11 can alternatively include a processor, with or without a storage medium, in which the determination procedure is performed by software, hardware, or a combination thereof. In another embodiment, the flow rate controller 11 can include semi-programmable hardware configured, for example, using a hardware descriptive language, such as Verilog. In another embodiment, the flow rate controller 11 of FIG. 1 is a computer, microprocessor-driven controller with software embedded. In yet another embodiment, the flow rate controller 11 can include additional features, such as a mechanism to automatically keep the saline flow on for several seconds after the RF is turned off to provide a post-coagulation cooling of the tissue or “quench,” which can increase the strength of the tissue seal.


As discussed herein, the saline can act as a shunt and divert energy away from target tissue. This is a phenomenon that can only occur with a bipolar device. In a monopolar device, saline can “pool” in the treatment area, and can, in some situations, divert energy by pooling. For the present discussion, shunting in connection with a bipolar device will be discussed.


In order to describe the underlying issue of saline shunting, an exemplary bipolar endoscopic electrosurgical device will be described in some detail. The bipolar electrosurgical device is described for purposes of illustrating the invention only, and it is understood that a wide variety of electrosurgical devices can be used in connection with the invention.


Preferably, the control device of the invention is used in connection with an electrosurgical device that is capable of controlling saline flow (for example, by controlling the location from which the saline is released from the electrosurgical device to the tissue). Any electrosurgical device that is capable of controlling saline flow is preferably used in connection with the invention described herein.



FIG. 7 shows an overall simple side schematic view of one embodiment of an electrosurgical device 5a that is designed to grasp, coagulate and then cut tissue. The electrosurgical device 5a includes a shaft 17, two opposing jaws 18 at the distal tip of the shaft 17, a collar 19 for rotating the entire shaft, a proximal handle 20, an actuation lever 21 which when squeezed will close the opposing jaws 18, a pair of paddles 22 to activate the built-in cutting mechanism (not shown in the figure), and a cable 23 attached to the handle that contains two electrical wires and one fluid channel (not shown individually in the figure). In use, tissue to be treated is positioned between the jaws 18 of the device 5a. The actuation lever 21 is then moved in direction of arrow 26, thereby drawing the opposing jaws 18 toward each other, to close the jaws 18 on the tissue. RF energy and conductive fluid, such as saline, are applied through the device and to the treatment site, thereby heating the tissue to coagulate, or achieve the desired treatment of the tissue. If desired, after coagulating the tissue between the jaws, the jaws can be held clamped together and the cutting mechanism can be actuated to cut tissue.



FIG. 8 shows a schematic close-up section view of the two jaws 18 at the distal tip of the shaft 17. In a preferred embodiment, each jaw 18 includes an electrode 25, a manifold 24, and a plurality of holes 26 in the electrode. Each jaw 18 further includes a jaw surface 29 that contacts the tissue to be treated. In the embodiment illustrated in FIG. 8, the jaw surface 29 is textured, so that it is capable of grasping the tissue to be treated. However, the jaw surface 29 need not be textured, and can include any type of desired surface configuration, such as serrations and the like, or can be provided with a smooth surface. In use, saline flows in a manifold 24 in the direction of arrows 30, wherein the manifold 24 distributes saline flow evenly to a plurality of holes 26 that are made in the jaw 18. Preferably, most of the structural material of each jaw 18 is fabricated from a material that is non-conductive electrically, such as nylon or other polymer such as liquid crystal polymer. This non-conductive material is shown in the figure as reference number 27. Further, in some embodiments, the jaw surface 29 can be fabricated from a nonconductive material. In a preferred embodiment, each jaw 18 further includes a groove 28 that is recessed from the jaw surface 29. In this embodiment, after the saline flows through the holes 26, it flows in the groove 28. When tissue is grasped between the jaws, saline can flow in the groove 28 between the electrode and the tissue, and exit through exit grooves 62 that are open to the outside at the proximal end of the jaws 18.



FIG. 9 shows an overall schematic top view of the electrosurgical device shown in FIGS. 7 and 8. As shown in FIG. 9, the jaws 18 can be provided in a loop configuration. FIG. 10 shows a close-up section of one of the loop jaws 18. In this embodiment, the jaws 18 are provided in a loop configuration to create a space 30 that allows a cutting mechanism 31 to move proximally and distally within the space 30. One of skill in the art would comprehend that the electrode configuration shown in FIG. 9 is simply an exemplary configuration, and the electrode need not be formed of two loops. For example, the electrosurgical device need not include a cutting mechanism, and the electrodes in these embodiments would not be required to include a space or recess for passage of the cutting mechanism. The invention contemplates any suitable electrode configuration used to treat tissue with RF energy and conductive fluid.


If the saline that flows from one electrode to the other is not boiling in any significant manner, a large fraction of the RF energy can be diverted away from target tissue. This “stealing” of RF energy tends to dramatically slow down the process of coagulating tissue and producing the desired hemostasis or aerostasis of the tissue. This situation is illustrated in FIG. 11. In this embodiment, tissue 32 grasped between the jaws 18 does not fill the jaws. Areas 34 and 35 show areas of air between the jaws 18. Saline liquid flows from the top electrode jaw to the lower electrode jaw in several locations: at area 33, located at the distal end of the jaws 18, at locations between tissue 32 and area 34, and between areas 34 and 35. These locations of saline flow between areas 34 and 35 represent the closest gap between jaws (area 35) and flow of saline along the tissue boundary 32, which are the most likely areas for saline flow between the jaws 18. Since most of the saline is not boiled, excess saline 36 drips off the lower jaw.


The saline shunting scenario can also be explained by using an electrical circuit as shown in FIG. 11a. Electrically, the tissue and the saline fluid shunt can be modeled as resistors in parallel. Using Ohm's Law one can calculate the percentage of total RF power that is dissipated in the saline shunt as:







%





RF





Power

=

100

[

1
+


R
s

/

R
t



]






In the embodiment illustrated in FIG. 11a, the total current (I) 50 from source 54 is split between two resistors, tissue electrical resistance (Rt), and saline shunt electrical resistance (Rs). This relationship is shown in the schematic graph of FIG. 11b, which shows the relationship of the ratio of saline to tissue resistance (Rs/Rt) to percent of power shunted into saline. As shown in the figure, when the resistance of the saline is equal to the tissue (Rs/Rt=1), half the power is shunted into the saline. For example, when the resistance of the saline is four times that of the tissue, then only 20% of the power is shunted into the saline.


One benefit of the flow rate control strategy described herein, where a high % boiling is maintained, is that the flow of saline from one electrode to the other is either eliminated altogether because all the flow boils off at the electrode/tissue interface, or a large fraction of the flow boils as it flows toward the other electrode. This second case is illustrated in FIG. 12, that is, where a large fraction of the saline flow boils as it flows toward the other electrode. Note that in comparison to FIG. 11, there is less saline flowing from the top jaw to the lower jaw, and where there is flow it is actively boiling, as indicated by the vapor bubbles shown in several locations 37 and 38. According to the invention, boiling of a large fraction of the saline assures that most of the RF power will be directed into the tissue to achieve coagulation in the fastest time.


One aspect of the control strategy of the invention is that the flow of saline is preferably primarily directed spatially against or very near the target tissue that is to receive the RF power. If the flow rate is not near where the RF power is turned into heat, the saline is not capable of protecting the tissue from desiccation by dissipating excess heat in the boiling process. Therefore, in a preferred embodiment, the flow of conductive fluid is directly primarily at the tissue treatment site.


Use


Typically a surgeon will grasp a small amount of tissue with the very tip of the device as shown in FIG. 13. If the electrode jaws are long relative to the length of the tissue segment being grasped, then saline exiting of holes 26 in the proximal part of the jaws may not be able to flow to the tip, but may leak out along the upper jaw. Though surface tension will act to keep saline flow in the groove 28, gravity can tend to cause the saline collect and flow down directly to the opposing jaw. This would result in the undesirable effects mentioned above. By providing two slidable gutters 39, the flow of saline can be collected and directed distally toward the tissue. In this embodiment, the saline can flow from one jaw to the other in areas 40, located on each side of the tissue being grasped, but with a large percentage boiling before reaching the other jaw. According to this embodiment, the gutters 39 can be fabricated from any material that is non-conducting, for example, plastic. The gutters can slide toward the distal end of the device as part of the activation of lever 21 shown in FIG. 7, to be stopped automatically by the presence of tissue. Alternatively the gutters 39 can be slid forward as part of a separate mechanism action. The gutters 39 can be fabricated from any suitable material that is non-conducting, for example, plastic.



FIG. 14 shows a schematic cross-sectional view of the gutters shown in FIG. 13. The cross-section in FIG. 14 illustrates the nonconducting portion 27 of the jaw 18, the saline manifold 24, the electrodes 25, holes 26, groove 28, space 30 for the cutting mechanism, and gutters 39. Near the distal end of the gutters, exit grooves 62 in the gutter can allow saline to flow through and onto the edge of the tissue even if the gutter is pressed snuggly against the tissue (shown in FIG. 8).



FIG. 15 and FIG. 16 illustrate an alternative embodiment of the electrosurgical device of the invention. In this embodiment, the electrosurgical device includes a mechanism for directing saline flow to where tissue is being heated using RF energy. Preferably, the mechanism for directing saline flow comprises one or more tissue activated valves. In FIG. 15, the jaw 18 of the device includes a pin 40 that is configured with a bulged portion 52 in the middle section of the plunger pin 40, so that the pin 40 can seat into a counter-sunk hole 26a in the electrode 25. Pin 40 preferably further includes a pin tip 41 that contacts tissue. Preferably, the pin tip 41 is rounded or atraumatic to reduce tissue trauma As illustrated in the figure, counter-sunk hole 26a includes a recessed portion 56 that is configured to receive the bulged portion 52, such that when seated within the recessed portion 56, the pin 40 prevents conductive fluid flow from the manifold 24 to the tissue being treated. Preferably, a guide tube 42 holds the pin 40 in position, and spring 43 provides force to push the bulged portion 52 of pin 40 into the recessed portion 56 and seal off the flow of saline from the manifold region 24. In use, the pin tip 41 contacts tissue when the jaws 18 compress tissue. When tissue is compressed, the tissue contacts the tip 41 and pushes the pin 40 upwards, unseating the bulged portion 52 of the pin 40 from the recessed portion 56, and allowing saline to flow in direction of arrows 44 through the annular space between the pin 40 and the counter-sunk hole 26a.



FIG. 16 shows a schematic view of one embodiment wherein a series of such tissue-activated valves functions to deliver saline flow only to areas of the jaws where tissue is compressed and to be RF-heated. Referring to FIGS. 15 and 16, tissue is compressed in the area labeled 60, and the holes 26a are open to allow saline flow to the tissue treatment site. As described above, tissue contacts tip 41, thereby pushing pin 40 upwards, unseating the bulged portion 52 of the pin 40 from the recessed portion 56 (shown in FIG. 15). This interaction allows saline to flow from the device 5a to the tissue being treated. In the area labeled 62 in the figure, tissue is not compressed between jaws 18 of the device 5a, and therefore the holes 26a are closed to the flow of saline from the device 5a. Because the tips 41 of pins 40 do not contact tissue, the pin 40 is not forced from its seated position within recessed portion 56 of the hole 26a (shown in FIG. 15).


Generally, the holes 26 or 26a of the electrode 25 supply conductive fluid to the treatment site. In an alternative embodiment, these holes are provided in the form of porous material such as metal. In this embodiment, the electrodes do not include discrete holes; rather, the electrode surface itself is porous to allow infusion of the conductive solution to the treatment site. Porous sintered metal is available in many materials (such as, for example, 316L stainless steel, titanium, Ni-Chrome, and the like) and shapes (such as cylinders, discs, plugs, and the like) from companies such as Porvair, located in Henderson, N.C.


Porous metal components can be formed by a sintered metal powder process or by injection molding a two-part combination of metal and a material that can be burned off to form pores that connect (open cell) to each other. Such methods are known in the art. In this embodiment, conductive fluid will flow out of the electrode everywhere the pores are open. Preferably, the exterior (that is, the portions of the components that do not comprise the portion of the device involved in tissue treatment) of such porous metal electrode components can be covered with a material that fills the pores and prevents both the flow of saline and the passing of electrical energy. Alternatively, the device can include gutters to prevent the flow of saline in areas where it is desired to prevent saline flow.


In yet another embodiment, a porous polymer is used in place of the porous metal. Although the polymer is non-conductive, the conductive solution provided will conduct the RF energy across the porous polymer wall and to the tissue to be treated. Suitable materials include high temperature open cell silicone foam and porous polycarbonates, among others. Porous ceramics also fall into this category, since they could distribute conductive fluid flow, withstand high temperatures and be machinable or moldable for manufacturing purposes. Preferably, the material used transmits both fluid flow and electrical energy; thus, materials with properties between high-electrical conductivity metals and low electrical conductivity polymers are also contemplated, such as porous carbon-filled polymers. In these embodiments, conductive fluid flow is distributed along the length of the electrodes, where porous material is used to fabricate the electrodes. All or a portion of the electrodes can be porous according to the invention.


While the invention has been described in relation to a bipolar electrosurgical device, it will be readily apparent that other electrosurgical devices can be easily adapted to be used in connection with the invention. For example, the electrosurgical device 5 in FIG. 1 can, in another embodiment, be provided as a monopolar device. In this embodiment, one of the wires going to the bipolar device would instead go to a ground pad dispersive electrode located on the patient's back or other suitable anatomical location. Minimally, the electrosurgical device will be capable of delivering RF power and conductive solution to tissue. For example, the device can comprise a straight needle having an interior lumen for transmitting conductive solution to the tissue. Alternatively, the electrosurgical device can comprise other configurations such as loops, forceps, blades, and the like.


Other suitable electrosurgical devices that can be used in connection with the invention described herein include, but are not limited to, devices described in U.S. patent application Ser. No. 09/668,403 (filed 22 Sep. 2000), U.S. Pat. No. 5,897,553 (issued 27 Apr. 1999), U.S. Pat. No. 6,063,081 (issued 16 May 2000), and U.S. Pat. No. 6,096,037 (issued 1 Aug. 2000).


Moreover, it will be readily apparent that other means can be used to provide heat to the tissue, in addition to the radio frequency power described herein.


One or more of the features of the previously described system can be built into a custom RF generator. This embodiment can provide one or more advantages. For example, this type of system can save space and reduce overall complexity for the user. This system can also enable the manufacturer to increase the power delivered into low impedance loads, thereby further reducing the time to achieve the desired tissue effects. This changes the curve of FIG. 5, by eliminating or reducing the slope of the low impedance ramp of power versus impedance.


To effectively treat thick tissues, it can be advantageous to have the ability to pulse the RF power on and off. Under some circumstances, the temperature deep in tissue can rise quickly past the 100° C. desiccation point even though the electrode/tissue interface is boiling at 100° C. This manifests itself as “popping,” as steam generated deep in the tissue boils too fast and erupts toward the surface. In one embodiment of the invention, a switch is provided on the control device or custom generator to allow the user to select a “pulse” mode of the RF power. Preferably, the RF power system in this embodiment is further controlled by software.


In some embodiments, it can be desirable to control the temperature of the conductive fluid before it is released from the electrosurgical device. In one embodiment, a heat exchanger is provided for the outgoing saline flow to either heat or chill the saline. Pre-heating the saline to a predetermined level below boiling reduces the transient warm-up time of the device as RF is initially turned on, thereby reducing the time to cause coagulation of tissue. Alternatively, pre-chilling the saline is useful when the surgeon desires to protect certain tissues at the electrode/tissue interface and treat only deeper tissue. One exemplary application of this embodiment is the treatment of varicose veins, where it is desirable to avoid thermal damage to the surface of the skin. At the same time, treatment is provided to shrink underlying blood vessels using thermal coagulation. The temperature of the conductive fluid prior to release from the surgical device can therefore be controlled, to provide the desired treatment effect.


In another embodiment, the flow rate controller is modified to provide for a saline flow rate that results in greater than 100% boiling at the tissue treatment site. For example, the selection switch 12 of the flow rate controller 11 (shown in FIG. 1) can include settings that correspond to 110%, 120% and greater percentages of boiling. These higher settings can be of value to a surgeon in such situations as when encountering thick tissue, wherein the thickness of the tissue can increase conduction away from the electrode jaws. Since the basic control strategy neglects heat conduction, setting for 100% boiling can result in 80% of 90% boiling, depending upon the amount of conduction. Given the teachings herein, the switch of the flow rate controller can accommodate any desirable flow rate settings, to achieve the desired saline boiling at the tissue treatment site.


Some embodiments of the invention can provide one or more advantages over current electrosurgical techniques and devices. For example, the invention preferably achieves the desired tissue effect (for example, coagulation, cutting, and the like) in a fast manner. In a preferred embodiment, by actively controlling the flow rate of saline, both in quantity (Q vs. P) and location (for example, using gutters to direct fluid distally to tissue, using holes to direct flow of fluid, or other similar methods) the electrosurgical device can create a hot non-desiccating electrode/tissue interface and thus a fast thermally induced tissue coagulation effect.


The invention can, in some embodiments, deliver fast treatment of tissue without using a temperature sensor built into the device or a custom special-purpose generator. In a preferred embodiment, there is no built-in temperature sensor or other type of tissue sensor, nor is there any custom generator. Preferably, the invention provides a means for controlling the flow rate to the device such that the device and flow rate controller can be used with a wide variety of general-purpose generators. Any general-purpose generator is useable in connection with the fluid delivery system and flow rate controller to provide the desired power; the flow rate controller will accept the power and constantly adjust the saline flow rate according to the control strategy. Preferably, the generator is not actively controlled by the invention, so that standard generators are useable according to the invention. Preferably, there is no active feedback from the device and the control of the saline flow rate is “open loop.” Thus, in this embodiment, the control of saline flow rate is not dependent on feedback, but rather the measurement of the RF power going out to the device.


In another aspect, the invention preferably provides an electrosurgical device design that is capable of quickly and effectively sealing a wide variety of tissue segment sizes. The electrosurgical device provides a number of characteristics that improve the ability to treat a wide variety of tissue size and thickness. For example, a preferred embodiment provides the ability to control the saline flow towards a high percentage boiling, for example, 80-100%. This reduces shunting of the RF by boiling off saline before it could flow to the other electrode, or by boiling the saline as it is in the process of flowing to the other electrode. In another aspect, one preferred embodiment includes gutters in connection with the electrodes. In this embodiment, saline flow is directed toward the tissue treatment site, thereby providing all or substantially all of the conductive fluid to the treatment site. Thus, the tissue being treated is sufficiently “protected” from desiccation by utilizing the controlled conductive fluid boiling described herein. Preferably, the tissue-activated jaws offer another way to provide the conductive fluid in proximity to where the RF power is turned into heat.


While a preferred embodiment of the present invention has been described, it should be understood that various changes, adaptations and modifications can be made therein without departing from the spirit of the invention and the scope of the appended claims. The scope of the invention should, therefore, be determined not with reference to the above description, but instead should be determined with reference to the appended claims along with their full scope of equivalents.


All publications and patent documents cited in this application are incorporated by reference in their entirety for all purposes to the extent they are not inconsistent with the teachings herein.

Claims
  • 1. An electrosurgical apparatus to provide controlled delivery of radio-frequency power and a fluid to an electrosurgical hand device to treat tissue, the apparatus comprising: a radio-frequency generator to deliver the radio-frequency power, the radio-frequency power from the radio-frequency generator selectable at a radio-frequency power level;a pump to deliver the fluid;a primer to prime the hand device with the fluid;a control system comprising an open loop control system with respect to the tissue, the open loop control system having a functional relationship relating a flow of the fluid to be delivered by the pump to the radio-frequency power level, the functional relationship to increase the flow of the fluid in response to an increase in the radio-frequency power level and to decrease the flow of the fluid in response to a decrease in the radio-frequency power level;a selection switch which changes the functional relationship relating the flow of the fluid to be delivered by the pump to the radio-frequency power level; andwherein the functional relationship relating a flow of the fluid to be delivered by the pump to the radio-frequency power level resides in a storage medium of the apparatus for use by a microprocessor, the functional relationship in the form of a mathematical equation having a proportionality constant and the selection switch changes the functional relationship by changing the proportionality constant.
  • 2. The apparatus of claim 1 wherein: the pump comprises a peristaltic pump.
  • 3. The apparatus of claim 1 wherein: the primer comprises a switch located on the apparatus.
  • 4. An electrosurgical apparatus to provide controlled delivery of radio-frequency power and a fluid to an electrosurgical hand device to treat tissue, the apparatus comprising: a radio-frequency generator to deliver the radio-frequency power, the radio-frequency power from the radio-frequency generator selectable at a radio-frequency power level;a pump to deliver the fluid;a primer to prime the hand device with the fluid;a control system comprising an open loop control system with respect to the tissue, the open loop control system having a functional relationship relating a flow of the fluid to be delivered by the pump to the radio-frequency power level over a range of radio-frequency power levels;a selection switch which changes the functional relationship relating the flow of the fluid to be delivered by the pump to the radio-frequency power level over the range of radio-frequency power levels; andwherein the functional relationship relating a flow of the fluid to be delivered by the pump to the radio-frequency power level over a range of radio-frequency power levels resides in a storage medium of the apparatus for use by a microprocessor, the functional relationship in the form of a mathematical equation having a proportionality constant and the selection switch changes the functional relationship by changing the proportionality constant.
  • 5. An electrosurgical apparatus to provide controlled delivery of radio-frequency power and a fluid to an electrosurgical hand device to treat tissue, the apparatus comprising: a radio-frequency generator to deliver the radio-frequency power, the radio-frequency power from the radio-frequency generator selectable at a radio-frequency power level;a pump to deliver the fluid;a control system comprising a functional relationship relating a flow of the fluid to be delivered by the pump to the radio-frequency power level, the functional relationship to increase the flow of the fluid in response to an increase in the radio-frequency power level and to decrease the flow of the fluid in response to a decrease in the radio-frequency power level;a selection switch which changes the flow of the fluid at the radio-frequency power level; andwherein the functional relationship relating a flow of the fluid to be delivered by the pump to the radio-frequency power level resides in a storage medium of the apparatus for use by a microprocessor, the functional relationship in the form of a mathematical equation having a proportionality constant and the selection switch changes the flow of the fluid at the radio-frequency power level by changing the proportionality constant.
  • 6. The apparatus of claim 5 further comprising: a primer to prime the hand device with the fluid.
  • 7. The apparatus of claim 5 wherein: the pump comprises a peristaltic pump.
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 09/797,049, filed Mar. 1, 2001, now U.S. Pat. No. 6,702,810, which claimed priority under 35 U.S.C. 119(e) to U.S. provisional application Ser. No. 60/187,114, filed Mar. 6, 2000.

US Referenced Citations (971)
Number Name Date Kind
623022 Johnson Apr 1899 A
1735271 Groff Nov 1929 A
1814791 Ende Jul 1931 A
2002594 Wappler et al. May 1935 A
2031682 Wappler et al. Feb 1936 A
2102270 Hyams Dec 1937 A
2275167 Bierman Mar 1942 A
2888928 Seiger Jun 1959 A
3163166 Brent et al. Dec 1964 A
3682130 Jeffers Aug 1972 A
3750650 Ruttgers Aug 1973 A
3901241 Allen, Jr. Aug 1975 A
4037590 Dohring et al. Jul 1977 A
4060088 Morrison, Jr. et al. Nov 1977 A
4116198 Roos Sep 1978 A
4244371 Farin Jan 1981 A
4276874 Wolvek et al. Jul 1981 A
4301802 Poler Nov 1981 A
4307720 Weber, Jr. Dec 1981 A
4321931 Hon Mar 1982 A
4326529 Doss et al. Apr 1982 A
4342218 Fox Aug 1982 A
4355642 Alferness Oct 1982 A
4381007 Doss Apr 1983 A
4532924 Auth et al. Aug 1985 A
4567890 Ohta et al. Feb 1986 A
4602628 Allen, Jr. Jul 1986 A
4671274 Sorochenko Jun 1987 A
4674499 Pao Jun 1987 A
4919129 Weber, Jr. Apr 1990 A
4920982 Goldstein May 1990 A
4931047 Broadwin et al. Jun 1990 A
4932952 Wojciechowicz, Jr. Jun 1990 A
4943290 Rexroth et al. Jul 1990 A
4950232 Ruzicka et al. Aug 1990 A
4976711 Parins et al. Dec 1990 A
4985030 Melzer et al. Jan 1991 A
4998933 Eggers et al. Mar 1991 A
5009656 Reimels Apr 1991 A
5013312 Parins et al. May 1991 A
5035696 Rydell Jul 1991 A
5071419 Rydell et al. Dec 1991 A
5080660 Buelna Jan 1992 A
5122138 Manwaring Jun 1992 A
5125928 Parins et al. Jun 1992 A
5147357 Rose et al. Sep 1992 A
5151102 Kamiyama et al. Sep 1992 A
5156613 Sawyer Oct 1992 A
5167659 Ohtomo et al. Dec 1992 A
5171311 Rydell et al. Dec 1992 A
5190541 Abele et al. Mar 1993 A
5195959 Smith Mar 1993 A
5197963 Parins Mar 1993 A
5197964 Parins Mar 1993 A
5217460 Knoepfler Jun 1993 A
5234428 Kaufman Aug 1993 A
5242441 Avitall Sep 1993 A
5242442 Hirschfeld Sep 1993 A
5254117 Rigby Oct 1993 A
5269780 Roos Dec 1993 A
5269781 Hewell, III Dec 1993 A
5277696 Hagen Jan 1994 A
5281215 Milder Jan 1994 A
5281216 Klicek Jan 1994 A
5282799 Rydell Feb 1994 A
5290286 Parins Mar 1994 A
5300087 Knoepfler Apr 1994 A
5313943 Houser et al. May 1994 A
5318589 Lichtman Jun 1994 A
5322503 Desai Jun 1994 A
5330521 Cohen Jul 1994 A
5334193 Nardella Aug 1994 A
5336220 Ryan Aug 1994 A
5342357 Nardella Aug 1994 A
5342359 Rydell Aug 1994 A
5348554 Imran et al. Sep 1994 A
5364394 Mehl Nov 1994 A
5383874 Jackson et al. Jan 1995 A
5383876 Nardella Jan 1995 A
5395312 Desai Mar 1995 A
5395363 Billings et al. Mar 1995 A
5401272 Perkins Mar 1995 A
5403311 Abele et al. Apr 1995 A
5403312 Yates et al. Apr 1995 A
5405344 Williamson et al. Apr 1995 A
5405376 Mulier et al. Apr 1995 A
5417672 Nita et al. May 1995 A
5417709 Slater May 1995 A
5431168 Webster et al. Jul 1995 A
5431649 Mulier et al. Jul 1995 A
5433708 Nichols et al. Jul 1995 A
5437662 Nardella Aug 1995 A
5437664 Cohen et al. Aug 1995 A
5441498 Perkins Aug 1995 A
5441503 Considine et al. Aug 1995 A
5445638 Rydell et al. Aug 1995 A
5456682 Edwards et al. Oct 1995 A
5456684 Schmidt et al. Oct 1995 A
5458596 Lax et al. Oct 1995 A
5458597 Edwards et al. Oct 1995 A
5458598 Feinberg et al. Oct 1995 A
5460629 Shlain et al. Oct 1995 A
5462521 Brucker et al. Oct 1995 A
5472441 Edwards et al. Dec 1995 A
5472443 Cordis et al. Dec 1995 A
5487385 Avitall Jan 1996 A
5490819 Nicholas et al. Feb 1996 A
5500012 Brucker et al. Mar 1996 A
5514130 Baker May 1996 A
5522815 Durgin, Jr. et al. Jun 1996 A
5536267 Edwards et al. Jul 1996 A
5540562 Giter Jul 1996 A
5542928 Evans et al. Aug 1996 A
5542945 Fritzsch Aug 1996 A
5556397 Long Sep 1996 A
5558671 Yates Sep 1996 A
5562503 Ellman et al. Oct 1996 A
5562702 Huitema et al. Oct 1996 A
5562703 Desai Oct 1996 A
5564440 Swartz et al. Oct 1996 A
5569242 Lax et al. Oct 1996 A
5569243 Kortenbach et al. Oct 1996 A
5573424 Poppe Nov 1996 A
5573533 Strul Nov 1996 A
5575810 Swanson et al. Nov 1996 A
5584872 LaFontaine et al. Dec 1996 A
5599346 Edwards et al. Feb 1997 A
5599350 Schulze et al. Feb 1997 A
5605539 Buelna et al. Feb 1997 A
5609151 Mulier et al. Mar 1997 A
5633578 Eggers et al. May 1997 A
5637110 Pennybacker et al. Jun 1997 A
5640955 Ockuly et al. Jun 1997 A
5643197 Brucker et al. Jul 1997 A
5647869 Goble et al. Jul 1997 A
5647871 Levine et al. Jul 1997 A
5653692 Masterson et al. Aug 1997 A
5660836 Knowlton Aug 1997 A
5676662 Fleischhacker et al. Oct 1997 A
5676693 LaFontaine Oct 1997 A
5681282 Eggers et al. Oct 1997 A
5681294 Osborne et al. Oct 1997 A
5683366 Eggers et al. Nov 1997 A
5683384 Gough et al. Nov 1997 A
5687723 Avitall Nov 1997 A
5688270 Yates et al. Nov 1997 A
5693045 Eggers Dec 1997 A
5697281 Eggers et al. Dec 1997 A
5697536 Eggers et al. Dec 1997 A
5697882 Eggers et al. Dec 1997 A
5697909 Eggers et al. Dec 1997 A
5697927 Imran et al. Dec 1997 A
5702386 Stern et al. Dec 1997 A
5709680 Yates et al. Jan 1998 A
5713896 Nardella Feb 1998 A
5718241 Ben-Haim et al. Feb 1998 A
5718701 Shai et al. Feb 1998 A
5718703 Chin Feb 1998 A
5722400 Ockuly et al. Mar 1998 A
5725524 Mulier et al. Mar 1998 A
5730127 Avitall Mar 1998 A
5735846 Panescu et al. Apr 1998 A
5743903 Stern et al. Apr 1998 A
5746739 Sutter May 1998 A
5749869 Lindenmeier et al. May 1998 A
5755717 Yates et al. May 1998 A
5755753 Knowlton May 1998 A
5766153 Eggers et al. Jun 1998 A
5766167 Eggers et al. Jun 1998 A
5785705 Baker Jul 1998 A
5785706 Bednarek Jul 1998 A
5792140 Tu et al. Aug 1998 A
5797905 Fleischman et al. Aug 1998 A
5797960 Stevens et al. Aug 1998 A
5800413 Swartz et al. Sep 1998 A
5800482 Pomeranz et al. Sep 1998 A
5807393 Williamson et al. Sep 1998 A
5807395 Mulier et al. Sep 1998 A
5810764 Eggers et al. Sep 1998 A
5810805 Sutcu et al. Sep 1998 A
5810811 Yates et al. Sep 1998 A
5817093 Williamson et al. Oct 1998 A
5823956 Roth et al. Oct 1998 A
5827271 Buysse et al. Oct 1998 A
5827281 Levin Oct 1998 A
5833703 Manushakian Nov 1998 A
5843019 Eggers et al. Dec 1998 A
5843021 Edwards et al. Dec 1998 A
5843078 Sharkey Dec 1998 A
5843152 Tu et al. Dec 1998 A
5855614 Stevens et al. Jan 1999 A
5860951 Eggers et al. Jan 1999 A
5860974 Abele Jan 1999 A
5861002 Desai Jan 1999 A
5861021 Thome et al. Jan 1999 A
5868739 Lindenmeier et al. Feb 1999 A
5871469 Eggers et al. Feb 1999 A
5871524 Knowlton Feb 1999 A
5873855 Eggers et al. Feb 1999 A
5876398 Mulier et al. Mar 1999 A
5879348 Owens et al. Mar 1999 A
5888198 Eggers et al. Mar 1999 A
5891095 Eggers et al. Apr 1999 A
5891141 Rydell Apr 1999 A
5891142 Eggers et al. Apr 1999 A
5893848 Negus et al. Apr 1999 A
5895355 Schaer Apr 1999 A
5895417 Pomeranz et al. Apr 1999 A
5897553 Mulier et al. Apr 1999 A
5902272 Eggers et al. May 1999 A
5902328 LaFontaine et al. May 1999 A
5904711 Flom et al. May 1999 A
5906613 Mulier et al. May 1999 A
5913854 Maguire et al. Jun 1999 A
5913856 Chia et al. Jun 1999 A
5919191 Lennox et al. Jul 1999 A
5919219 Knowlton Jul 1999 A
5921982 Lesh et al. Jul 1999 A
5921983 Shannon, Jr. Jul 1999 A
5925045 Reimels et al. Jul 1999 A
5935123 Edwards et al. Aug 1999 A
5944715 Goble Aug 1999 A
5948011 Knowlton Sep 1999 A
5951549 Richardson et al. Sep 1999 A
5954716 Sharkey et al. Sep 1999 A
5957919 Laufer Sep 1999 A
5964755 Edwards Oct 1999 A
5971983 Lesh Oct 1999 A
5976128 Schilling et al. Nov 1999 A
5980504 Sharkey et al. Nov 1999 A
5980516 Mulier et al. Nov 1999 A
5989248 Tu et al. Nov 1999 A
5992418 de la Rama et al. Nov 1999 A
5993412 Deily et al. Nov 1999 A
6003517 Sheffield et al. Dec 1999 A
6004316 Laufer Dec 1999 A
6004319 Goble et al. Dec 1999 A
6007570 Sharkey et al. Dec 1999 A
6010500 Sherman et al. Jan 2000 A
6015391 Rishton et al. Jan 2000 A
6015407 Rieb et al. Jan 2000 A
6016809 Mulier et al. Jan 2000 A
6017338 Brucker et al. Jan 2000 A
6018676 Davis et al. Jan 2000 A
6019757 Scheldrup Feb 2000 A
6024733 Eggers et al. Feb 2000 A
6027501 Goble et al. Feb 2000 A
6030379 Panescu et al. Feb 2000 A
6030381 Jones Feb 2000 A
6032077 Pomeranz Feb 2000 A
6032674 Eggers et al. Mar 2000 A
6033398 Farley et al. Mar 2000 A
6035238 Ingle et al. Mar 2000 A
6036687 Laufer et al. Mar 2000 A
6045532 Eggers et al. Apr 2000 A
6047700 Eggers et al. Apr 2000 A
6048333 Lennox et al. Apr 2000 A
6053172 Hovda et al. Apr 2000 A
6053912 Panescu et al. Apr 2000 A
6056744 Edwards May 2000 A
6056745 Panescu et al. May 2000 A
6056746 Goble May 2000 A
6056747 Saadat et al. May 2000 A
6059781 Yamanashi et al. May 2000 A
6063079 Hovda et al. May 2000 A
6063081 Mulier et al. May 2000 A
6066134 Eggers et al. May 2000 A
6066139 Ryan et al. May 2000 A
6068627 Orszulak et al. May 2000 A
6068653 LaFontaine May 2000 A
6071280 Edwards et al. Jun 2000 A
6073051 Sharkey et al. Jun 2000 A
6074389 Levine et al. Jun 2000 A
6080151 Swartz et al. Jun 2000 A
6081749 Ingle et al. Jun 2000 A
6083237 Huitema et al. Jul 2000 A
6086585 Hovda et al. Jul 2000 A
6086586 Hooven Jul 2000 A
6091995 Ingle et al. Jul 2000 A
6093186 Goble Jul 2000 A
6095149 Sharkey et al. Aug 2000 A
6096037 Mulier et al. Aug 2000 A
6099514 Sharkey et al. Aug 2000 A
6102046 Weinstein et al. Aug 2000 A
6105581 Eggers et al. Aug 2000 A
6109268 Thapliyal et al. Aug 2000 A
6113596 Hooven et al. Sep 2000 A
6113597 Eggers et al. Sep 2000 A
6117109 Eggers et al. Sep 2000 A
6122549 Sharkey et al. Sep 2000 A
H1904 Yates et al. Oct 2000 H
6126682 Sharkey et al. Oct 2000 A
6135999 Fanton et al. Oct 2000 A
6141576 Littmann et al. Oct 2000 A
6142992 Cheng et al. Nov 2000 A
6149620 Baker et al. Nov 2000 A
6159194 Eggers et al. Dec 2000 A
6159208 Hovda et al. Dec 2000 A
6165169 Panescu et al. Dec 2000 A
6165175 Wampler et al. Dec 2000 A
6168594 LaFontaine et al. Jan 2001 B1
6171275 Webster, Jr. Jan 2001 B1
6174308 Goble et al. Jan 2001 B1
6174309 Wrublewski et al. Jan 2001 B1
6176857 Ashley Jan 2001 B1
6179824 Eggers et al. Jan 2001 B1
6179836 Eggers et al. Jan 2001 B1
6183469 Thapliyal et al. Feb 2001 B1
6190381 Olsen et al. Feb 2001 B1
6190384 Ouchi Feb 2001 B1
6193715 Wrublewski et al. Feb 2001 B1
6193716 Shannon, Jr. Feb 2001 B1
6203542 Ellsberry et al. Mar 2001 B1
6210402 Olsen et al. Apr 2001 B1
6210406 Webster Apr 2001 B1
6210410 Farin et al. Apr 2001 B1
6210411 Hofmann et al. Apr 2001 B1
6212426 Swanson Apr 2001 B1
6216704 Ingle et al. Apr 2001 B1
6217576 Tu et al. Apr 2001 B1
6221039 Durgin et al. Apr 2001 B1
6221069 Daikuzono Apr 2001 B1
6224592 Eggers et al. May 2001 B1
6224593 Ryan et al. May 2001 B1
6226554 Tu et al. May 2001 B1
6228078 Eggers et al. May 2001 B1
6228082 Baker et al. May 2001 B1
6231591 Desai May 2001 B1
6235020 Cheng et al. May 2001 B1
6236891 Ingle et al. May 2001 B1
6238387 Miller, III May 2001 B1
6238391 Olsen et al. May 2001 B1
6238393 Mulier et al. May 2001 B1
6241753 Knowlton Jun 2001 B1
6241754 Swanson et al. Jun 2001 B1
6251110 Wampler Jun 2001 B1
6254600 Willink et al. Jul 2001 B1
6258086 Ashley et al. Jul 2001 B1
6258087 Edwards et al. Jul 2001 B1
6261311 Sharkey et al. Jul 2001 B1
6264650 Hovda et al. Jul 2001 B1
6264651 Underwood et al. Jul 2001 B1
6264652 Eggers et al. Jul 2001 B1
6264654 Swartz et al. Jul 2001 B1
6266551 Osadchy et al. Jul 2001 B1
6277112 Underwood et al. Aug 2001 B1
6280440 Gocho Aug 2001 B1
6283961 Underwood et al. Sep 2001 B1
6283988 Laufer et al. Sep 2001 B1
6283989 Laufer et al. Sep 2001 B1
6290715 Sharkey et al. Sep 2001 B1
6293942 Goble et al. Sep 2001 B1
6293945 Parins et al. Sep 2001 B1
6296636 Cheng et al. Oct 2001 B1
6296638 Davison et al. Oct 2001 B1
6296640 Wampler et al. Oct 2001 B1
6299633 Laufer Oct 2001 B1
6302903 Mulier et al. Oct 2001 B1
6306134 Goble et al. Oct 2001 B1
6309387 Eggers et al. Oct 2001 B1
6311090 Knowlton Oct 2001 B1
6312408 Eggers et al. Nov 2001 B1
6312430 Wilson et al. Nov 2001 B1
6315777 Comben Nov 2001 B1
6322549 Eggers et al. Nov 2001 B1
6322559 Daulton et al. Nov 2001 B1
6327505 Medhkour et al. Dec 2001 B1
6328735 Curley et al. Dec 2001 B1
6328736 Mulier et al. Dec 2001 B1
6336926 Goble Jan 2002 B1
6350262 Ashley Feb 2002 B1
6350276 Knowlton Feb 2002 B1
6352533 Ellman et al. Mar 2002 B1
6355032 Hovda et al. Mar 2002 B1
6358245 Edwards et al. Mar 2002 B1
6358248 Mulier et al. Mar 2002 B1
6363937 Hovda et al. Apr 2002 B1
6371956 Wilson et al. Apr 2002 B1
6379350 Sharkey et al. Apr 2002 B1
6379351 Thapliyal et al. Apr 2002 B1
6391025 Weinstein et al. May 2002 B1
6391028 Fanton et al. May 2002 B1
6402742 Blewett et al. Jun 2002 B1
6409722 Hoey et al. Jun 2002 B1
6409723 Edwards Jun 2002 B1
H2037 Yates et al. Jul 2002 H
6416507 Eggers et al. Jul 2002 B1
6416508 Eggers et al. Jul 2002 B1
6416509 Goble et al. Jul 2002 B1
6425877 Edwards Jul 2002 B1
6432103 Ellsberry et al. Aug 2002 B1
6440130 Mulier et al. Aug 2002 B1
6443952 Mulier et al. Sep 2002 B1
6451017 Moutafis et al. Sep 2002 B1
6458123 Brucker et al. Oct 2002 B1
6458130 Frazier et al. Oct 2002 B1
6461350 Underwood et al. Oct 2002 B1
6461354 Olsen et al. Oct 2002 B1
6461357 Sharkey et al. Oct 2002 B1
6464695 Hovda et al. Oct 2002 B2
6468270 Hovda et al. Oct 2002 B1
6468274 Alleyne et al. Oct 2002 B1
6468275 Wampler et al. Oct 2002 B1
6471698 Edwards et al. Oct 2002 B1
6475216 Mulier et al. Nov 2002 B2
6478793 Cosman et al. Nov 2002 B1
6482202 Goble et al. Nov 2002 B1
6485490 Wampler et al. Nov 2002 B2
6488680 Francischelli et al. Dec 2002 B1
6493589 Medhkour et al. Dec 2002 B1
6494902 Hoey et al. Dec 2002 B2
6497704 Ein-Gai Dec 2002 B2
6497705 Comben Dec 2002 B2
6506189 Rittman, III et al. Jan 2003 B1
6508815 Strul et al. Jan 2003 B1
6517536 Hooven et al. Feb 2003 B2
6526320 Mitchell Feb 2003 B2
6537248 Mulier et al. Mar 2003 B2
6537272 Christopherson et al. Mar 2003 B2
6539265 Medhkour et al. Mar 2003 B2
6558379 Batchelor et al. May 2003 B1
6558385 McClurken et al. May 2003 B1
6575969 Rittman et al. Jun 2003 B1
6577902 Laufer et al. Jun 2003 B1
6579288 Swanson et al. Jun 2003 B1
6585732 Mulier et al. Jul 2003 B2
6602248 Sharps et al. Aug 2003 B1
6603988 Dowlatshahi Aug 2003 B2
6610060 Mulier et al. Aug 2003 B2
6613048 Mulier et al. Sep 2003 B2
6623515 Mulier et al. Sep 2003 B2
6626899 Houser et al. Sep 2003 B2
6635034 Cosmescu Oct 2003 B1
6645202 Pless et al. Nov 2003 B1
6666862 Jain et al. Dec 2003 B2
6669692 Nelson et al. Dec 2003 B1
6676660 Wampler Jan 2004 B2
6679882 Kornerup Jan 2004 B1
6682501 Nelson et al. Jan 2004 B1
6682527 Strul Jan 2004 B2
6682528 Frazier et al. Jan 2004 B2
6685700 Behl et al. Feb 2004 B2
6685701 Orszulak et al. Feb 2004 B2
6685704 Greep Feb 2004 B2
6689129 Baker Feb 2004 B2
6689131 McClurken Feb 2004 B2
6692489 Heim et al. Feb 2004 B1
6694984 Habib Feb 2004 B2
6695837 Howell Feb 2004 B2
6695840 Schulze Feb 2004 B2
6699240 Francischelli Mar 2004 B2
6699242 Heggeness Mar 2004 B2
6699244 Carranza et al. Mar 2004 B2
6699268 Kordis et al. Mar 2004 B2
6702810 McClurken et al. Mar 2004 B2
6702812 Cosmescu Mar 2004 B2
6706039 Mulier et al. Mar 2004 B2
6712074 Edwards et al. Mar 2004 B2
6712811 Underwood et al. Mar 2004 B2
6712813 Ellman et al. Mar 2004 B2
6712816 Hung et al. Mar 2004 B2
6716211 Mulier et al. Apr 2004 B2
6719754 Underwood et al. Apr 2004 B2
6723094 Desinger Apr 2004 B1
6726683 Shaw Apr 2004 B1
6726684 Woloszko et al. Apr 2004 B1
6726686 Buysse et al. Apr 2004 B2
6730081 Desai May 2004 B1
6733496 Sharkey et al. May 2004 B2
6733498 Paton et al. May 2004 B2
6733501 Levine May 2004 B2
6736810 Hoey et al. May 2004 B2
6740058 Lal et al. May 2004 B2
6740079 Eggers et al. May 2004 B1
6740082 Shadduck May 2004 B2
6740084 Ryan May 2004 B2
6740102 Hess et al. May 2004 B2
6743197 Edwards Jun 2004 B1
6743229 Buysse et al. Jun 2004 B2
6743230 Lutze et al. Jun 2004 B2
6746447 Davison et al. Jun 2004 B2
6755825 Shoenman et al. Jun 2004 B2
6755827 Mulier et al. Jun 2004 B2
6757565 Sharkey et al. Jun 2004 B2
6758846 Goble et al. Jul 2004 B2
6761718 Madsen Jul 2004 B2
6764487 Mulier et al. Jul 2004 B2
6766202 Underwood et al. Jul 2004 B2
6766817 Da Silva Jul 2004 B2
6770070 Balbierz Aug 2004 B1
6770071 Woloszko et al. Aug 2004 B2
6770072 Truckai et al. Aug 2004 B1
6772012 Ricart et al. Aug 2004 B2
6772013 Ingle et al. Aug 2004 B1
6775575 Bommannan et al. Aug 2004 B2
6776780 Mulier et al. Aug 2004 B2
6780177 Shafirstein et al. Aug 2004 B2
6780180 Goble et al. Aug 2004 B1
6786906 Cobb Sep 2004 B1
6796981 Wham et al. Sep 2004 B2
6800077 Mucko et al. Oct 2004 B1
6802842 Ellman et al. Oct 2004 B2
6802843 Truckai et al. Oct 2004 B2
6808525 Latterell et al. Oct 2004 B2
6813520 Truckai et al. Nov 2004 B2
6814714 Novak et al. Nov 2004 B1
6814731 Swanson Nov 2004 B2
6821273 Mollenauer Nov 2004 B2
6827713 Bek et al. Dec 2004 B2
6827725 Batchelor et al. Dec 2004 B2
6832996 Woloszko Dec 2004 B2
6832997 Uchida et al. Dec 2004 B2
6835195 Schulze et al. Dec 2004 B2
6836688 Ingle et al. Dec 2004 B2
6843789 Goble Jan 2005 B2
6845264 Skladnev et al. Jan 2005 B1
6849073 Hoey et al. Feb 2005 B2
6855145 Ciarrocca Feb 2005 B2
6858028 Mulier et al. Feb 2005 B2
6860882 Battles et al. Mar 2005 B2
6863669 Spitzer Mar 2005 B2
6864686 Novak et al. Mar 2005 B2
6881214 Cosman et al. Apr 2005 B2
6882885 Levy, Jr. et al. Apr 2005 B2
6887237 McGaffigan May 2005 B2
6887240 Lands et al. May 2005 B1
6893435 Goble May 2005 B2
6893440 Durgin et al. May 2005 B2
6896672 Eggers et al. May 2005 B1
6896674 Woloszko et al. May 2005 B1
6899712 Moutafis et al. May 2005 B2
6905497 Truckai et al. Jun 2005 B2
6905499 Mucko et al. Jun 2005 B1
6911019 Mulier et al. Jun 2005 B2
6915806 Pacek et al. Jul 2005 B2
6918404 Da Silva Jul 2005 B2
6921398 Carmel et al. Jul 2005 B2
6921399 Carmel et al. Jul 2005 B2
6923803 Goble Aug 2005 B2
6923805 LaFontaine et al. Aug 2005 B1
6926706 Sealfon Aug 2005 B1
6926716 Baker et al. Aug 2005 B2
6926717 Garito et al. Aug 2005 B1
6929640 Underwood et al. Aug 2005 B1
6929641 Goble et al. Aug 2005 B2
6929642 Xiao et al. Aug 2005 B2
6929644 Truckai et al. Aug 2005 B2
6929645 Battles et al. Aug 2005 B2
6932810 Ryan Aug 2005 B2
6932815 Sutter Aug 2005 B2
6942661 Swanson Sep 2005 B2
6949096 Davison et al. Sep 2005 B2
6949098 Mulier et al. Sep 2005 B2
6951559 Greep Oct 2005 B1
6953461 McClurken et al. Oct 2005 B2
6960204 Eggers et al. Nov 2005 B2
6960207 Vanney et al. Nov 2005 B2
6960210 Lands et al. Nov 2005 B2
6962589 Mulier et al. Nov 2005 B2
6964274 Ryan et al. Nov 2005 B1
6964661 Rioux et al. Nov 2005 B2
6966907 Goble Nov 2005 B2
6966909 Marshall et al. Nov 2005 B2
6971394 Sliwa, Jr. et al. Dec 2005 B2
6974452 Gille et al. Dec 2005 B1
6974453 Woloszko et al. Dec 2005 B2
6979332 Adams Dec 2005 B2
6984231 Goble et al. Jan 2006 B2
6986769 Nelson et al. Jan 2006 B2
6991631 Woloszko et al. Jan 2006 B2
7001380 Goble Feb 2006 B2
7001382 Gallo, Sr. Feb 2006 B2
7004941 Tvinnereim et al. Feb 2006 B2
7004942 Laird et al. Feb 2006 B2
7008419 Shadduck Mar 2006 B2
7008421 Daniel et al. Mar 2006 B2
7033348 Alfano et al. Apr 2006 B2
7033356 Latterell et al. Apr 2006 B2
7041096 Malis et al. May 2006 B2
7041101 Eggers May 2006 B2
7041102 Truckai et al. May 2006 B2
7052494 Goble et al. May 2006 B2
7060064 Allen et al. Jun 2006 B2
7063670 Sampson et al. Jun 2006 B2
7066586 Da Silva Jun 2006 B2
7066932 Morgan et al. Jun 2006 B1
7066936 Ryan Jun 2006 B2
7070596 Woloszko et al. Jul 2006 B1
7070604 Garito et al. Jul 2006 B1
7074217 Strul et al. Jul 2006 B2
7074219 Levine et al. Jul 2006 B2
7083601 Cosmescu Aug 2006 B1
7087051 Bourne et al. Aug 2006 B2
7087053 Vanney Aug 2006 B2
7094215 Davison et al. Aug 2006 B2
7101387 Garabedian et al. Sep 2006 B2
7104986 Hovda et al. Sep 2006 B2
7112199 Cosmescu Sep 2006 B2
7115139 McClurken et al. Oct 2006 B2
7125406 Given Oct 2006 B2
7147634 Nesbitt Dec 2006 B2
7147635 Ciarrocca Dec 2006 B2
7147637 Goble Dec 2006 B2
7147638 Chapman et al. Dec 2006 B2
7150746 DeCesare et al. Dec 2006 B2
7150747 McDonald et al. Dec 2006 B1
7150748 Ebbutt et al. Dec 2006 B2
7153300 Goble Dec 2006 B2
7156845 Mulier et al. Jan 2007 B2
7166105 Mulier et al. Jan 2007 B2
7166106 Bartel et al. Jan 2007 B2
7169143 Eggers et al. Jan 2007 B2
7169144 Hoey et al. Jan 2007 B2
7207471 Heinrich et al. Apr 2007 B2
7232440 Dumbauld et al. Jun 2007 B2
7247155 Hoey et al. Jul 2007 B2
7261711 Mulier et al. Aug 2007 B2
7309325 Mulier et al. Dec 2007 B2
7311708 McClurken Dec 2007 B2
7322974 Swoyer et al. Jan 2008 B2
7361175 Suslov Apr 2008 B2
7364579 Mulier et al. Apr 2008 B2
20010014819 Ingle et al. Aug 2001 A1
20010020167 Woloszko et al. Sep 2001 A1
20010023365 Medhkour et al. Sep 2001 A1
20010025178 Mulier et al. Sep 2001 A1
20010032002 McClurken et al. Oct 2001 A1
20010039419 Francischelli et al. Nov 2001 A1
20010041921 Mulier et al. Nov 2001 A1
20010051802 Woloszko et al. Dec 2001 A1
20010051804 Mulier et al. Dec 2001 A1
20020002393 Mitchell Jan 2002 A1
20020010463 Mulier et al. Jan 2002 A1
20020013582 Mulier et al. Jan 2002 A1
20020016589 Swartz et al. Feb 2002 A1
20020019628 Comben Feb 2002 A1
20020022870 Truckai et al. Feb 2002 A1
20020026186 Woloszko et al. Feb 2002 A1
20020026187 Swanson Feb 2002 A1
20020029036 Goble et al. Mar 2002 A1
20020035361 Houser et al. Mar 2002 A1
20020035387 Mulier et al. Mar 2002 A1
20020049438 Sharkey et al. Apr 2002 A1
20020049439 Mulier et al. Apr 2002 A1
20020049483 Knowlton Apr 2002 A1
20020058933 Christopherson et al. May 2002 A1
20020058935 Hoey et al. May 2002 A1
20020062123 McClurken et al. May 2002 A1
20020095150 Goble Jul 2002 A1
20020095151 Dahla et al. Jul 2002 A1
20020095152 Ciarrocca et al. Jul 2002 A1
20020099366 Dahla et al. Jul 2002 A1
20020115991 Edwards Aug 2002 A1
20020115992 Utley et al. Aug 2002 A1
20020120259 Lettice et al. Aug 2002 A1
20020120260 Morris et al. Aug 2002 A1
20020120261 Morris et al. Aug 2002 A1
20020128650 McClurken Sep 2002 A1
20020133148 Daniel et al. Sep 2002 A1
20020151884 Hoey et al. Oct 2002 A1
20020156511 Habib Oct 2002 A1
20020161364 Mulier et al. Oct 2002 A1
20020169446 Mulier et al. Nov 2002 A1
20020177846 Mulier et al. Nov 2002 A1
20020183733 Mulier et al. Dec 2002 A1
20020188284 To et al. Dec 2002 A1
20020193851 Silverman et al. Dec 2002 A1
20020198524 Mulier et al. Dec 2002 A1
20030014050 Sharkey et al. Jan 2003 A1
20030032954 Carranza et al. Feb 2003 A1
20030032955 Mulier et al. Feb 2003 A1
20030073989 Hoey et al. Apr 2003 A1
20030073993 Ciarrocca Apr 2003 A1
20030114850 McClurken et al. Jun 2003 A1
20030181902 Mulier et al. Sep 2003 A1
20030204185 Sherman et al. Oct 2003 A1
20030216733 McClurken et al. Nov 2003 A1
20040015162 McGaffigan Jan 2004 A1
20040015163 Buysse et al. Jan 2004 A1
20040015215 Fredricks et al. Jan 2004 A1
20040015216 DeSisto Jan 2004 A1
20040015218 Finch et al. Jan 2004 A1
20040019350 O'Brien et al. Jan 2004 A1
20040024395 Ellman et al. Feb 2004 A1
20040024396 Eggers Feb 2004 A1
20040024398 Hovda et al. Feb 2004 A1
20040024399 Sharps et al. Feb 2004 A1
20040030327 Golan Feb 2004 A1
20040030328 Eggers et al. Feb 2004 A1
20040030330 Brassell et al. Feb 2004 A1
20040030332 Knowlton et al. Feb 2004 A1
20040030333 Goble Feb 2004 A1
20040034340 Biscup Feb 2004 A1
20040034346 Stern et al. Feb 2004 A1
20040034349 Kirwan, Jr. et al. Feb 2004 A1
20040034400 Ingle et al. Feb 2004 A1
20040039429 Daniel et al. Feb 2004 A1
20040044341 Truckai et al. Mar 2004 A1
20040054363 Vaska et al. Mar 2004 A1
20040054365 Goble Mar 2004 A1
20040054366 Davison et al. Mar 2004 A1
20040054369 Nelson et al. Mar 2004 A1
20040054370 Given Mar 2004 A1
20040059328 Daniel et al. Mar 2004 A1
20040059363 Alvarez et al. Mar 2004 A1
20040064023 Ryan et al. Apr 2004 A1
20040064137 Pellegrino et al. Apr 2004 A1
20040068306 Shadduck Apr 2004 A1
20040068307 Goble Apr 2004 A1
20040073205 Treat et al. Apr 2004 A1
20040073208 Sutter Apr 2004 A1
20040078034 Acker et al. Apr 2004 A1
20040078037 Batchelor et al. Apr 2004 A1
20040078038 Desinger et al. Apr 2004 A1
20040082946 Malis et al. Apr 2004 A1
20040082952 Dycus et al. Apr 2004 A1
20040087937 Eggers et al. May 2004 A1
20040087939 Eggers et al. May 2004 A1
20040087940 Jahns et al. May 2004 A1
20040087943 Dycus et al. May 2004 A1
20040088029 Yamamoto May 2004 A1
20040092925 Rizoiu et al. May 2004 A1
20040092926 Hoey et al. May 2004 A1
20040097919 Wellman et al. May 2004 A1
20040102770 Goble May 2004 A1
20040102824 Sharkey et al. May 2004 A1
20040111136 Sharkey et al. Jun 2004 A1
20040111137 Sharkey et al. Jun 2004 A1
20040116923 Desinger Jun 2004 A1
20040122420 Amoah Jun 2004 A1
20040122423 Dycus et al. Jun 2004 A1
20040122494 Eggers et al. Jun 2004 A1
20040138654 Goble Jul 2004 A1
20040138655 McClurken et al. Jul 2004 A1
20040138657 Bourne et al. Jul 2004 A1
20040143257 Fuimaono Jul 2004 A1
20040143258 Fuimaono Jul 2004 A1
20040143259 Mulier et al. Jul 2004 A1
20040143263 Schechter et al. Jul 2004 A1
20040147902 McGuckin, Jr. et al. Jul 2004 A1
20040147916 Baker Jul 2004 A1
20040147922 Keppel Jul 2004 A1
20040147925 Buysse et al. Jul 2004 A1
20040162552 McClurken Aug 2004 A1
20040162554 Lee et al. Aug 2004 A1
20040162557 Tetzlaff et al. Aug 2004 A1
20040162572 Sauer Aug 2004 A1
20040167508 Wham et al. Aug 2004 A1
20040172111 Hijii et al. Sep 2004 A1
20040176760 Qiu Sep 2004 A1
20040176761 Desinger Sep 2004 A1
20040176762 Lawes et al. Sep 2004 A1
20040181219 Goble et al. Sep 2004 A1
20040181250 Adams et al. Sep 2004 A1
20040186469 Woloszko et al. Sep 2004 A1
20040186470 Goble et al. Sep 2004 A1
20040186535 Knowlton Sep 2004 A1
20040193148 Wham et al. Sep 2004 A1
20040193150 Sharkey et al. Sep 2004 A1
20040193152 Sutton et al. Sep 2004 A1
20040193211 Voegele et al. Sep 2004 A1
20040199156 Rioux et al. Oct 2004 A1
20040199160 Slater Oct 2004 A1
20040206365 Knowlton Oct 2004 A1
20040210213 Fuimaono et al. Oct 2004 A1
20040210214 Knowlton Oct 2004 A1
20040215181 Christopherson et al. Oct 2004 A1
20040215182 Lee Oct 2004 A1
20040215183 Hoey et al. Oct 2004 A1
20040215184 Eggers et al. Oct 2004 A1
20040215185 Truckai et al. Oct 2004 A1
20040215188 Mulier et al. Oct 2004 A1
20040215235 Jackson et al. Oct 2004 A1
20040215296 Ganz et al. Oct 2004 A1
20040220561 Kirwan, Jr. et al. Nov 2004 A1
20040220562 Garabedian et al. Nov 2004 A1
20040225288 Buysse et al. Nov 2004 A1
20040230190 Dahla et al. Nov 2004 A1
20040236322 Mulier et al. Nov 2004 A1
20040236324 Muller et al. Nov 2004 A1
20040243125 Dycus et al. Dec 2004 A1
20040243163 Casiano et al. Dec 2004 A1
20040249371 Dycus et al. Dec 2004 A1
20040249374 Tetzlaff et al. Dec 2004 A1
20040249425 Roy et al. Dec 2004 A1
20040260279 Goble et al. Dec 2004 A1
20040260280 Sartor Dec 2004 A1
20040260368 Ingle et al. Dec 2004 A1
20050010205 Hovda et al. Jan 2005 A1
20050010212 McClurken et al. Jan 2005 A1
20050015085 McClurken et al. Jan 2005 A1
20050015086 Platt Jan 2005 A1
20050015130 Gill Jan 2005 A1
20050021025 Buysse et al. Jan 2005 A1
20050021026 Baily Jan 2005 A1
20050021027 Shields et al. Jan 2005 A1
20050033278 McClurken et al. Feb 2005 A1
20050033292 Teitelbaum et al. Feb 2005 A1
20050038471 Chan et al. Feb 2005 A1
20050043728 Ciarrocca Feb 2005 A1
20050049583 Swanson Mar 2005 A1
20050049586 Daniel et al. Mar 2005 A1
20050055019 Skarda Mar 2005 A1
20050055020 Skarda Mar 2005 A1
20050059966 McClurken et al. Mar 2005 A1
20050070888 Dimatteo et al. Mar 2005 A1
20050070891 DeSisto Mar 2005 A1
20050070894 McClurken Mar 2005 A1
20050070896 Daniel et al. Mar 2005 A1
20050080410 Rioux et al. Apr 2005 A1
20050080413 Canady Apr 2005 A1
20050085804 McGaffigan Apr 2005 A1
20050085809 Mucko et al. Apr 2005 A1
20050085880 Truckai et al. Apr 2005 A1
20050090816 McClurken et al. Apr 2005 A1
20050090819 Goble Apr 2005 A1
20050096649 Adams May 2005 A1
20050096651 Truckai et al. May 2005 A1
20050101951 Wham et al. May 2005 A1
20050101952 Lands et al. May 2005 A1
20050101965 Ryan May 2005 A1
20050107778 Rioux et al. May 2005 A1
20050107779 Ellman et al. May 2005 A1
20050107784 Moses et al. May 2005 A1
20050107786 Canady May 2005 A1
20050113820 Goble et al. May 2005 A1
20050113825 Cosmescu May 2005 A1
20050124987 Goble Jun 2005 A1
20050130929 Boyd Jun 2005 A1
20050131402 Ciarrocca et al. Jun 2005 A1
20050137590 Lawes et al. Jun 2005 A1
20050137662 Morris et al. Jun 2005 A1
20050143729 Francischelli et al. Jun 2005 A1
20050154385 Heim et al. Jul 2005 A1
20050154433 Levy, Jr. et al. Jul 2005 A1
20050159739 Paul et al. Jul 2005 A1
20050159740 Paul et al. Jul 2005 A1
20050159778 Heinrich et al. Jul 2005 A1
20050159797 Chandran et al. Jul 2005 A1
20050165444 Hart et al. Jul 2005 A1
20050171524 Stern et al. Aug 2005 A1
20050171526 Rioux et al. Aug 2005 A1
20050171532 Ciarrocca Aug 2005 A1
20050171533 Latterell et al. Aug 2005 A1
20050171534 Habib Aug 2005 A1
20050171583 Mosher et al. Aug 2005 A1
20050177150 Amoah et al. Aug 2005 A1
20050177209 Leung et al. Aug 2005 A1
20050187543 Underwood et al. Aug 2005 A1
20050187599 Sharkey et al. Aug 2005 A1
20050203503 Edwards et al. Sep 2005 A1
20050203504 Wham et al. Sep 2005 A1
20050209591 Sutter Sep 2005 A1
20050209621 Gordon et al. Sep 2005 A1
20050222602 Sutter et al. Oct 2005 A1
20050222611 WeitKamp Oct 2005 A1
20050228372 Truckai et al. Oct 2005 A1
20050245918 Sliwa, Jr. et al. Nov 2005 A1
20050245921 Strul et al. Nov 2005 A1
20050245922 Goble Nov 2005 A1
20050245923 Christopherson et al. Nov 2005 A1
20050250477 Eastwood et al. Nov 2005 A1
20050251128 Amoah Nov 2005 A1
20050251134 Woloszko et al. Nov 2005 A1
20050256519 Goble et al. Nov 2005 A1
20050261676 Hall et al. Nov 2005 A1
20050261677 Hall et al. Nov 2005 A1
20050267465 Hillier et al. Dec 2005 A1
20050267467 Paul et al. Dec 2005 A1
20050267468 Truckai et al. Dec 2005 A1
20050267469 Blocher Dec 2005 A1
20050273092 G. et al. Dec 2005 A1
20050273097 Ryan Dec 2005 A1
20050277915 DeCesare et al. Dec 2005 A1
20050277916 DeCesare et al. Dec 2005 A1
20050277917 Garito et al. Dec 2005 A1
20050283147 Yachi Dec 2005 A1
20050283148 Janssen et al. Dec 2005 A1
20050283149 Thorne et al. Dec 2005 A1
20050283150 Moutafis et al. Dec 2005 A1
20050283151 Ebbutt et al. Dec 2005 A1
20050288661 Sauvageau et al. Dec 2005 A1
20050288665 Woloszko Dec 2005 A1
20060004356 Bilski et al. Jan 2006 A1
20060009760 Mulier et al. Jan 2006 A1
20060009762 Whayne Jan 2006 A1
20060015097 Mulier et al. Jan 2006 A1
20060020265 Ryan Jan 2006 A1
20060025765 Landman et al. Feb 2006 A1
20060025766 Heinrich et al. Feb 2006 A1
20060030912 Eggers et al. Feb 2006 A1
20060036235 Swoyer et al. Feb 2006 A1
20060036237 Davison et al. Feb 2006 A1
20060036239 Canady Feb 2006 A1
20060041254 Francischelli et al. Feb 2006 A1
20060041255 Eggers et al. Feb 2006 A1
20060047275 Goble Mar 2006 A1
20060047280 Goble et al. Mar 2006 A1
20060047331 Lax et al. Mar 2006 A1
20060052770 Mulier et al. Mar 2006 A1
20060064085 Schechter et al. Mar 2006 A1
20060064101 Arramon Mar 2006 A1
20060074411 Carmel et al. Apr 2006 A1
20060074414 Mulier et al. Apr 2006 A1
20060079872 Eggleston Apr 2006 A1
20060079888 Mulier et al. Apr 2006 A1
20060084968 Truckai et al. Apr 2006 A1
20060095026 Ricart et al. May 2006 A1
20060095031 Ormsby May 2006 A1
20060095034 Garito et al. May 2006 A1
20060095075 Burkinshaw et al. May 2006 A1
20060095103 Eggers et al. May 2006 A1
20060100619 McClurken et al. May 2006 A1
20060106376 Godara et al. May 2006 A1
20060106379 O'Brien et al. May 2006 A1
20060111705 Janzen et al. May 2006 A1
20060111709 Goble et al. May 2006 A1
20060111710 Goble et al. May 2006 A1
20060111711 Goble May 2006 A1
20060111741 Nardella May 2006 A1
20060116675 McClurken et al. Jun 2006 A1
20060122593 Jun et al. Jun 2006 A1
20060129145 Woloszko et al. Jun 2006 A1
20060129185 Paternuosto Jun 2006 A1
20060142757 Daniel et al. Jun 2006 A1
20060149225 McClurken Jul 2006 A1
20060167446 Pozzato Jul 2006 A1
20060167449 Mulier et al. Jul 2006 A1
20060167451 Cropper Jul 2006 A1
20060178667 Sartor et al. Aug 2006 A1
20060178668 Albritton, IV Aug 2006 A1
20060178670 Woloszko et al. Aug 2006 A1
20060178699 Surti Aug 2006 A1
20060184164 Malis et al. Aug 2006 A1
20060184167 Vaska et al. Aug 2006 A1
20060189977 Allen et al. Aug 2006 A1
20060189979 Esch et al. Aug 2006 A1
20060195079 Eberl Aug 2006 A1
20060200123 Ryan Sep 2006 A1
20060217700 Garito et al. Sep 2006 A1
20060217701 Young et al. Sep 2006 A1
20060217707 Daniel et al. Sep 2006 A1
20060224154 Shadduck et al. Oct 2006 A1
20060235286 Stone et al. Oct 2006 A1
20060235377 Earley et al. Oct 2006 A1
20060235379 McClurken et al. Oct 2006 A1
20060241577 Balbierz et al. Oct 2006 A1
20060241587 Heim et al. Oct 2006 A1
20060241588 Heim et al. Oct 2006 A1
20060241589 Heim et al. Oct 2006 A1
20060247614 Sampson et al. Nov 2006 A1
20060259025 Dahla Nov 2006 A1
20060259031 Carmel et al. Nov 2006 A1
20060259070 Livneh Nov 2006 A1
20060264927 Ryan Nov 2006 A1
20060264929 Goble et al. Nov 2006 A1
20060264931 Chapman et al. Nov 2006 A1
20060271033 Ein-Gal Nov 2006 A1
20060271036 Garabedian et al. Nov 2006 A1
20060271042 Latterell et al. Nov 2006 A1
20060276783 Cosmescu Dec 2006 A1
20060276785 Asahara et al. Dec 2006 A1
20070000501 Wert et al. Jan 2007 A1
20070010812 Mittelstein et al. Jan 2007 A1
20070016182 Lipson et al. Jan 2007 A1
20070049920 McClurken et al. Mar 2007 A1
20070093808 Mulier et al. Apr 2007 A1
20070118114 Miller et al. May 2007 A1
20070208332 Mulier et al. Sep 2007 A1
20080015563 Hoey et al. Jan 2008 A1
20080071270 Baker et al. Mar 2008 A1
Foreign Referenced Citations (35)
Number Date Country
1 007 960 May 1957 DE
0 175 595 Mar 1986 EP
0 895 756 Feb 1999 EP
1 095 627 May 2001 EP
1 157 666 Nov 2001 EP
2 235 669 Jan 1975 FR
57-117843 Jul 1982 JP
5-092009 Apr 1993 JP
7-124245 May 1995 JP
WO 9003152 Apr 1990 WO
WO 9402077 Feb 1994 WO
WO 9426228 Nov 1994 WO
WO 9505781 Mar 1995 WO
WO 9509570 Apr 1995 WO
WO 9517222 Jun 1995 WO
WO 9634571 Nov 1996 WO
WO 9705829 Feb 1997 WO
WO 9705829 Feb 1997 WO
WO 9716127 May 1997 WO
WO 9814131 Apr 1998 WO
WO 9838932 Sep 1998 WO
WO 9903414 Jan 1999 WO
WO 9920213 Apr 1999 WO
WO 9958070 Nov 1999 WO
WO 9966850 Dec 1999 WO
WO 0078240 Dec 2000 WO
WO 0126570 Apr 2001 WO
WO 0128444 Apr 2001 WO
WO 0135845 May 2001 WO
WO 0160273 Aug 2001 WO
WO 0166026 Sep 2001 WO
WO 0180757 Nov 2001 WO
WO 2005122938 Dec 2005 WO
WO 2006062916 Jun 2006 WO
WO 2006062939 Jun 2006 WO
Related Publications (1)
Number Date Country
20040138655 A1 Jul 2004 US
Provisional Applications (1)
Number Date Country
60187114 Mar 2000 US
Continuations (1)
Number Date Country
Parent 09797049 Mar 2001 US
Child 10746222 US